Summary
The company's fiscal 2018 first quarter was a sharp reversal from the prior-year period. Revenue fell 30.0% to $2,911,000. The company swung to an operating loss of $723,000 from operating income a year earlier. Net loss was $495,000, and diluted EPS was -$0.02. Operating margin was -24.8%, down 30.2 percentage points from the prior-year quarter. The quarter also marked the adoption of ASC 606 using the full retrospective method. That accounting change restated certain previously reported results, so comparisons to earlier periods reflect the new standard. The reported figures in the filing are the restated amounts.
The revenue decline came from several parts of the business. Management said lower biometrics software license sales, lower services revenue, and the absence of income from a patent arrangement all weighed on results. A large software license sale to the U.S. Marines in the first quarter of 2017 did not repeat in the first quarter of 2018. Imaging software license sales were slightly higher, and software maintenance revenue rose on better retention of renewals. Services backlog was minimal at the end of the quarter. The company continues to sell biometrics software and services to government and commercial customers. Commercial biometrics remains an emerging market, and management said it cannot predict future revenue from those markets. Management also noted that it cannot predict whether the U.S. Marines will purchase the software again. The loss of that large government order is a clear example of the quarter-to-quarter volatility in this business.
Cost trends were mixed. Cost of software licenses and cost of services both fell, which helped offset some of the revenue pressure. Research and development expense was essentially unchanged. Sales and marketing expense rose slightly on higher salary, advertising, tradeshow, and travel costs, partly offset by lower spending on sales agents and commissions. General and administrative expense edged lower on reduced stock-based compensation, partly offset by higher professional fees. Interest income increased because of higher rates on money market accounts. The company recorded an income tax benefit for the quarter, and the IRS completed its examination of the 2015 tax return with no changes to reported tax. Management said it has assessed its deferred tax assets and concluded no valuation allowance was needed. That conclusion depends on future earnings and reversing deferred tax liabilities.
Cash flow and balance sheet items showed the strain. Operating cash flow was -$803,000 for the quarter. Capital expenditures were $96,000, up from the prior-year quarter. Deferred revenue was $2,396,000, down 1.0% from a year earlier. The company said its cash and cash equivalents should be sufficient to fund operations for at least the next twelve months, although it cannot assure that it will not need additional financing. The MD&A points to several risks. Revenue depends on winning government and commercial projects, and government budgets and procurement timing can shift. The patent arrangement may not produce more income. DSL royalties are unlikely to return. Commercial biometrics markets are still developing. The company also carries forward-looking risk factors from its 2017 Form 10-K.
The quarter's results show a business with a smaller revenue base and a cost structure that did not shrink as quickly. Operating expenses were roughly flat in several categories while revenue dropped 30.0%. That combination pushed operating margin deeply negative. Management's plan remains focused on legacy government biometrics markets and expansion into commercial biometrics. Execution on new projects and maintenance renewals will matter for the top line. The company's cash position gives it time, but the lack of a large license repeat and the unpredictable timing of government orders remain central risks. Investors will watch whether the maintenance and imaging gains can offset further swings in biometrics license sales. The deferred revenue decline of 1.0% suggests that near-term maintenance revenue may not grow much without new contracts. The company's ability to convert its pipeline into signed deals will determine whether the operating loss narrows in coming quarters.
Forecast
No forward guidance in this quarter's filings.
Reported figures
GAAP, from SEC filings| Metric | Q1 FY2018 | Q4 FY2017 | QoQ | Q1 FY2017 | YoY |
|---|---|---|---|---|---|
| Revenue | $144.0K | $335.0K | -57.0% | $374.0K | -61.5% |
| Gross profit | $94.0K | $233.0K | -59.7% | $158.0K | -40.5% |
| Gross margin | 65.3% | 69.5% | -4.3 pp | 42.3% | +23.0 pp |
| Research & development | $1.9M | $1.9M | -0.5% | $1.9M | +1.0% |
| Sales & marketing | $924.0K | $1.0M | -7.7% | $942.0K | -1.9% |
| General & administrative | $785.0K | $935.0K | -16.0% | $790.0K | -0.6% |
| Total operating expenses | $3.6M | $3.9M | -7.4% | $4.1M | -10.3% |
| Operating income (loss) | -$723.0K | -$478.0K | -51.3% | $386.0K | -287.3% |
| Operating margin | -502.1% | -142.7% | -359.4 pp | 103.2% | -605.3 pp |
| Net income (loss) | -$495.0K | -$581.0K | +14.8% | $405.0K | -222.2% |
| Net margin | -343.8% | -173.4% | -170.3 pp | 108.3% | -452.0 pp |
| Diluted EPS | -$0.02 | -$0.03 | +$0.01 | $0.02 | -$0.04 |
Risks
Revenue in FY2018 Q1 was $2.91 million, down 30.0% from the prior-year quarter, primarily due to lower biometrics software license sales including no large U.S. Marines software license sale in Q1 2018 versus Q1 2017; management cannot predict whether the U.S. Marines will purchase this software again.
Operating income swung to a loss of $0.72 million in FY2018 Q1 from operating income of $0.22 million in the prior-year quarter, net income swung to a loss of $0.50 million from net income of $0.30 million, and operating cash flow was negative $0.80 million in the current quarter.
Software license revenue decreased 41% from $2.5 million in Q1 2017 to $1.5 million in Q1 2018, services revenue decreased 62% from $0.4 million to $0.1 million, and services backlog was minimal as of March 31, 2018.
The company's strategy includes expanding into new commercial biometrics markets, but management states it is unable to predict future revenue from these emerging markets.
Royalties decreased 100% from $43,000 in Q1 2017 to zero in Q1 2018, and no patent related income was recorded in Q1 2018 versus $91,000 in Q1 2017; management considers it unlikely that DSL royalties will be received in future periods and cannot predict further patent monetization income.
As of March 31, 2018, the company had $5.2 million of deferred tax assets with no valuation allowance; management will continue to assess the need for a valuation allowance and may adjust it if evidence regarding realizability changes.
Summary, forecast, risks and KPIs are extracted from AWARE INC /MA/'s SEC filings for Q1 FY2018 (10-Q / 10-K and the 8-K earnings release); GAAP figures in the summary are checked against the reported XBRL data. They can contain errors; the filings are authoritative. Processed Nov 9, 2026.